Developer docs
API playgroundTry for free, no card

Search company profiles

scPharmaceuticals

Full company profile

uuid0000wne

Namestring
scPharmaceuticals
Legal namestring
scPharmaceuticals Inc.
Company typeenum
Public
Founded yearint
2014
Descriptiontext

scPharmaceuticals Inc. was a specialty biopharmaceutical company founded in 2014 and headquartered in Lexington, Massachusetts, that developed and commercialized subcutaneous drug delivery products for chronic disease management. The company's core product is FUROSCIX, an FDA-approved On-body Infusor that delivers furosemide subcutaneously for the treatment of fluid overload (congestion) in heart failure patients who are not adequately controlled on oral diuretics. The underlying technology pairs a proprietary concentrated liquid furosemide formulation (protected by a pending patent on solubility-optimized compositions covering pH, excipients, and buffers) with a wearable delivery device that enables outpatient self-administration, providing an alternative to IV diuretic infusions delivered in clinical settings.

Short descriptiontext

scPharmaceuticals was a specialty biopharmaceutical company that developed and commercialized FUROSCIX, an FDA-approved On-body Infusor for subcutaneous furosemide delivery to treat fluid overload in heart failure patients. Acquired by MannKind Corporation for up to $360 million in August 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBurlington, United States
HQ citystring
Burlington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
subcutaneous drug delivery, heart failure therapeutics, specialty biopharmaceuticals, diuretic infusion devices, pharmaceutical drug delivery
Industry1 code
PRIMARYHLAHAIAE
Wearable Injectors & On-Body Delivery Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code2 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals — Cardiology / Heart Failure
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1FUROSCIX Product Sales
TypeHardware Sales
Description

Revenue generated from sales of FUROSCIX (furosemide injection) delivered via the On-body Infusor for heart failure patients with fluid overload. The product was commercialized in the US market following FDA approval.

mannkindcorp.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1FUROSCIX
Description

On-body infusor for furosemide injection, a treatment for fluid overload in heart failure patients

mannkindcorp.com
Core offering1 text field

scPharmaceuticals develops and commercializes FUROSCIX, an on-body infusor that delivers subcutaneous furosemide for treatment of fluid overload (congestion) in heart failure patients, enabling outpatient administration as an alternative to IV diuretic infusions. The company also develops proprietary concentrated liquid furosemide formulations optimized for subcutaneous delivery. FUROSCIX is FDA-approved for adult and pediatric use, with a ReadyFlow Autoinjector sNDA under FDA review.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Reduced healthcare costs through outpatient treatment vs. IV clinic visits
+1 more record
Product overview1 text field

scPharmaceuticals was a specialty pharmaceutical company focused on developing and commercializing subcutaneous drug delivery solutions for chronic diseases. The company's primary product was FUROSCIX, an on-body infusor that delivers furosemide subcutaneously for heart failure patients with fluid overload. scPharmaceuticals was acquired by MannKind Corporation in August 2025 for $360 million and is now operated as a wholly owned subsidiary, with FUROSCIX integrated into MannKind's cardiometabolic portfolio alongside Afrezza, V-Go, and Tyvaso DPI products.

Product and service1 record
1FUROSCIX On-body Infusor (furosemide injection)
CategorySpecialty Pharmaceuticals — Heart Failure / Cardiology
Description

An on-body infusor that delivers subcutaneous furosemide injection for treatment of fluid overload (congestion) in heart failure patients, enabling outpatient treatment without IV access. FDA-approved for adult use and, post-acquisition, for pediatric use.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-25
Description

MannKind Corporation acquired scPharmaceuticals for up to $360 million in August 2025 to expand its cardiometabolic treatment portfolio with FUROSCIX. scPharmaceuticals operates as a wholly owned subsidiary of MannKind. Blackstone provided strategic financing support for the acquisition.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Insulet's Omnipod is a body-worn, on-body infusion patch pump for subcutaneous drug delivery, the closest analog to the FUROSCIX On-body Infusor in wearable subcutaneous delivery technology. Both companies commercialize wearable injectors designed for patient self-administration outside clinical settings.

TypeDirect peer
Description

Halozyme's ENHANZE platform enables high-volume subcutaneous delivery of therapeutics via recombinant hyaluronidase, directly addressing the same subcutaneous drug delivery problem FUROSCIX solves for furosemide. Both companies' core technology unlocks outpatient subcutaneous administration of drugs traditionally given intravenously.

TypeDirect peer
Description

Enable Injections develops large-volume wearable subcutaneous delivery devices (enFuse) that compete for the same outpatient subcutaneous infusion use case as the FUROSCIX On-body Infusor. Both companies target the same clinical value proposition of moving IV therapies into patient self-administered home settings.

TypeDirect peer
Description

Cytokinetics develops cardiac myosin modulators (e.g., aficamten for HCM) for heart failure and related cardiovascular indications, addressing the same heart failure prescriber audience as FUROSCIX. Both companies target the cardiology channel for innovative therapies addressing cardiac dysfunction.

TypeDirect peer
Description

Lexicon developed sotagliflozin for heart failure and cardiorenal conditions, addressing the same heart failure and CKD populations targeted by FUROSCIX. Both companies pursued differentiated outpatient therapies for fluid management and cardiorenal outcomes.

TypeBroad incumbent
Description

West Pharmaceutical is a leading provider of drug containment and delivery components including elastomeric stoppers, prefilled syringe systems, and wearable injector platforms serving the same pharmaceutical customers developing subcutaneous biologics and small molecules. Broad incumbent in injectable drug delivery infrastructure.

TypeBroad incumbent
Description

BD is a broad incumbent in drug delivery devices including prefilled syringes, autoinjectors, and wearable injection systems used across pharmaceutical customers. Its Pharmaceutical Systems segment competes with the FUROSCIX delivery approach as one of multiple portfolio offerings.

TypeBroad incumbent
Description

AstraZeneca commercializes Farxiga (dapagliflozin) for heart failure with reduced and preserved ejection fraction, addressing the same HF patient population as FUROSCIX through an oral once-daily therapy. Broad incumbent in cardiovascular and cardiorenal therapeutics with established cardiology channel access.

TypeOthers
Description

United Therapeutics is a strategic partner of MannKind (Tyvaso DPI leverages MannKind's Technosphere platform) and operates in cardiopulmonary therapeutics including pulmonary hypertension and heart failure adjacencies, sharing commercial channels and ecosystem relationships relevant to FUROSCIX.

TypeOthers
Description

MannKind is the parent company that acquired scPharmaceuticals for $360M in August 2025 and now owns the FUROSCIX franchise. Not a comparable peer in market position but relevant as the operating umbrella for the asset and integrator of FUROSCIX with Afrezza, V-Go, and Tyvaso DPI.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

scPharmaceuticals

Specialty Pharmaceuticals — Cardiology / Heart Failurescpharmaceuticals.com

scPharmaceuticals was a specialty biopharmaceutical company that developed and commercialized FUROSCIX, an FDA-approved On-body Infusor for subcutaneous furosemide delivery to treat fluid overload in heart failure patients. Acquired by MannKind Corporation for up to $360 million in August 2025.

What scPharmaceuticals does

scPharmaceuticals Inc. was a specialty biopharmaceutical company founded in 2014 and headquartered in Lexington, Massachusetts, that developed and commercialized subcutaneous drug delivery products for chronic disease management. The company's core product is FUROSCIX, an FDA-approved On-body Infusor that delivers furosemide subcutaneously for the treatment of fluid overload (congestion) in heart failure patients who are not adequately controlled on oral diuretics. The underlying technology pairs a proprietary concentrated liquid furosemide formulation (protected by a pending patent on solubility-optimized compositions covering pH, excipients, and buffers) with a wearable delivery device that enables outpatient self-administration, providing an alternative to IV diuretic infusions delivered in clinical settings.

scPharmaceuticals firmographics

Firmographics
Name
scPharmaceuticals
Legal name
scPharmaceuticals Inc.
Website
https://scpharmaceuticals.com
Company type
Public
Founded year
2014
Operating status
Acquired
Headcount range
11–50 employees
Short description
scPharmaceuticals was a specialty biopharmaceutical company that developed and commercialized FUROSCIX, an FDA-approved On-body Infusor for subcutaneous furosemide delivery to treat fluid overload in heart failure patients. Acquired by MannKind Corporation for up to $360 million in August 2025.
Ownership category
akta.pro rank

scPharmaceuticals industry classification

Industry
Product category
Specialty Pharmaceuticals — Cardiology / Heart Failure
NAICS
Medical Equipment and Supplies Manufacturing (3391), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAHAIAE
Wearable Injectors & On-Body Delivery Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Subcutaneous drug delivery
  • Heart failure therapeutics
  • Specialty biopharmaceuticals
  • Diuretic infusion devices
  • Pharmaceutical drug delivery

Where scPharmaceuticals is headquartered

Location

Headquarters

HQ city
Burlington
HQ country
United States
HQ region
North America

Markets served

scPharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. FUROSCIX Product Sales: Revenue generated from sales of FUROSCIX (furosemide injection) delivered via the On-body Infusor for heart failure patients with fluid overload. The product was commercialized in the US market following FDA approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

scPharmaceuticals product offering

Product offering

Core offering

scPharmaceuticals develops and commercializes FUROSCIX, an on-body infusor that delivers subcutaneous furosemide for treatment of fluid overload (congestion) in heart failure patients, enabling outpatient administration as an alternative to IV diuretic infusions. The company also develops proprietary concentrated liquid furosemide formulations optimized for subcutaneous delivery. FUROSCIX is FDA-approved for adult and pediatric use, with a ReadyFlow Autoinjector sNDA under FDA review.

Product overview

scPharmaceuticals was a specialty pharmaceutical company focused on developing and commercializing subcutaneous drug delivery solutions for chronic diseases. The company's primary product was FUROSCIX, an on-body infusor that delivers furosemide subcutaneously for heart failure patients with fluid overload. scPharmaceuticals was acquired by MannKind Corporation in August 2025 for $360 million and is now operated as a wholly owned subsidiary, with FUROSCIX integrated into MannKind's cardiometabolic portfolio alongside Afrezza, V-Go, and Tyvaso DPI products.

Differentiator

Problem solved

Functional benefit

Brands

  • FUROSCIX: On-body infusor for furosemide injection, a treatment for fluid overload in heart failure patients

Products and services

  • FUROSCIX On-body Infusor (furosemide injection) An on-body infusor that delivers subcutaneous furosemide injection for treatment of fluid overload (congestion) in heart failure patients, enabling outpatient treatment without IV access. FDA-approved for adult use and, post-acquisition, for pediatric use.

Quantifiable outcome

  • Reduced healthcare costs through outpatient treatment vs. IV clinic visits
  • +1 more outcomes

Companies that use scPharmaceuticals

Customer profile

Segments2 records

Ideal customer profiles2 records

scPharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

scPharmaceuticals partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • MannKind CorporationcoreStrategic or Co-development Partner · 25 August 2025MannKind Corporation acquired scPharmaceuticals for up to $360 million in August 2025 to expand its cardiometabolic treatment portfolio with FUROSCIX. scPharmaceuticals operates as a wholly owned subsidiary of MannKind. Blackstone provided strategic financing support for the acquisition.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

scPharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Insulet Corporation: Insulet's Omnipod is a body-worn, on-body infusion patch pump for subcutaneous drug delivery, the closest analog to the FUROSCIX On-body Infusor in wearable subcutaneous delivery technology. Both companies commercialize wearable injectors designed for patient self-administration outside clinical settings.
  • Halozyme Therapeutics: Halozyme's ENHANZE platform enables high-volume subcutaneous delivery of therapeutics via recombinant hyaluronidase, directly addressing the same subcutaneous drug delivery problem FUROSCIX solves for furosemide. Both companies' core technology unlocks outpatient subcutaneous administration of drugs traditionally given intravenously.
  • Enable Injections: Enable Injections develops large-volume wearable subcutaneous delivery devices (enFuse) that compete for the same outpatient subcutaneous infusion use case as the FUROSCIX On-body Infusor. Both companies target the same clinical value proposition of moving IV therapies into patient self-administered home settings.
  • Cytokinetics: Cytokinetics develops cardiac myosin modulators (e.g., aficamten for HCM) for heart failure and related cardiovascular indications, addressing the same heart failure prescriber audience as FUROSCIX. Both companies target the cardiology channel for innovative therapies addressing cardiac dysfunction.
  • Lexicon Pharmaceuticals: Lexicon developed sotagliflozin for heart failure and cardiorenal conditions, addressing the same heart failure and CKD populations targeted by FUROSCIX. Both companies pursued differentiated outpatient therapies for fluid management and cardiorenal outcomes.

Broad incumbents

  • West Pharmaceutical Services: West Pharmaceutical is a leading provider of drug containment and delivery components including elastomeric stoppers, prefilled syringe systems, and wearable injector platforms serving the same pharmaceutical customers developing subcutaneous biologics and small molecules. Broad incumbent in injectable drug delivery infrastructure.
  • Becton Dickinson: BD is a broad incumbent in drug delivery devices including prefilled syringes, autoinjectors, and wearable injection systems used across pharmaceutical customers. Its Pharmaceutical Systems segment competes with the FUROSCIX delivery approach as one of multiple portfolio offerings.
  • AstraZeneca: AstraZeneca commercializes Farxiga (dapagliflozin) for heart failure with reduced and preserved ejection fraction, addressing the same HF patient population as FUROSCIX through an oral once-daily therapy. Broad incumbent in cardiovascular and cardiorenal therapeutics with established cardiology channel access.

Others

  • United Therapeutics: United Therapeutics is a strategic partner of MannKind (Tyvaso DPI leverages MannKind's Technosphere platform) and operates in cardiopulmonary therapeutics including pulmonary hypertension and heart failure adjacencies, sharing commercial channels and ecosystem relationships relevant to FUROSCIX.
  • MannKind Corporation: MannKind is the parent company that acquired scPharmaceuticals for $360M in August 2025 and now owns the FUROSCIX franchise. Not a comparable peer in market position but relevant as the operating umbrella for the asset and integrator of FUROSCIX with Afrezza, V-Go, and Tyvaso DPI.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

scPharmaceuticals social profiles

Digital presence

scPharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

scPharmaceuticals leadership team

Management profile

Number of profiles

scPharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

scPharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about scPharmaceuticals

What does scPharmaceuticals do?

scPharmaceuticals develops and commercializes FUROSCIX, an on-body infusor that delivers subcutaneous furosemide for treatment of fluid overload (congestion) in heart failure patients, enabling outpatient administration as an alternative to IV diuretic infusions. The company also develops proprietary concentrated liquid furosemide formulations optimized for subcutaneous delivery. FUROSCIX is FDA-approved for adult and pediatric use, with a ReadyFlow Autoinjector sNDA under FDA review.

Is scPharmaceuticals a public or private company?

scPharmaceuticals is a public company. It is classified as corporate owned and is currently acquired.

When was scPharmaceuticals founded?

scPharmaceuticals was founded in 2014. It employs 11 to 50 people.

Where is scPharmaceuticals based?

scPharmaceuticals is headquartered in Burlington, United States, in the North America region.

How does scPharmaceuticals make money?

One revenue line is on record: FUROSCIX Product Sales.

Who are scPharmaceuticals's main competitors?

Direct peers on record are Insulet Corporation, Halozyme Therapeutics, Enable Injections, Cytokinetics and Lexicon Pharmaceuticals. Broad incumbents are West Pharmaceutical Services, Becton Dickinson and AstraZeneca. Others are United Therapeutics and MannKind Corporation.

Does scPharmaceuticals have an API?

No public API is recorded for scPharmaceuticals.

What industry is scPharmaceuticals in?

scPharmaceuticals's product category is Specialty Pharmaceuticals — Cardiology / Heart Failure. Its primary akta.pro industry code is HLAHAIAE, Wearable Injectors & On-Body Delivery Systems. Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Financial TimesBreaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets – Company AnnouncementA promotional press release issued on behalf of Avant Technologies Inc. profiles multiple biotech companies positioned to benefit from an FDA regulatory shift facilitating cell and gene therapy development, with the featured companies (Avant, MannKind, Vertex Pharmaceuticals, Fate Therapeutics, and Ardelyx) reporting clinical progress and business updates in chronic disease treatments including diabetes, kidney disease, and autoimmune conditions. Avant highlighted its cell encapsulation technology through two joint ventures—Insulinova with SGAustria targeting diabetes and Klothonova with Austrianova targeting age-related diseases—while each profiled company cited milestones such as FDA decisions, clinical trial data, and revenue growth. The article is a paid advertisement with disclosure that the publisher holds shares in Avant Technologies and received compensation for the coverage.GlobeNewswireMannKind Provides Business Updates and 2026 Growth DriversMannKind provided business updates for 2026, citing a record Q4 net revenue exceeding $100 million and the acquisition of scPharmaceuticals. The company highlighted FDA decisions on Afrezza label updates and FUROSCIX autoinjector, with first-patient enrollment in nintedanib DPI studies in December. It also noted a second dry powder investigational molecule under development with United Therapeutics.GlobeNewswireMannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic CareMannKind Corporation completed its acquisition of scPharmaceuticals Inc. on October 7, 2025, making scPharmaceuticals a wholly owned subsidiary. The tender offer valued scPharmaceuticals at up to $6.35 per share ($5.35 cash plus non-tradable CVRs worth up to $1.00), with approximately 73.47% of shares tendered. The transaction is expected to diversify and accelerate MannKind's double-digit revenue growth by adding FUROSCIX to its cardiometabolic portfolio, contributing to an annualized run rate exceeding $370 million.LinkedInInvesting in Precision Medicine: VC | PE | M&A - August Round-Up 2025In August 2025, the biotech, pharma, and health tech sectors experienced active M&A deals, fundraisings, and private equity investments. Major acquisitions included Gilead’s $350 million purchase of Interius BioTherapeutics and MannKind’s acquisition of scPharmaceuticals for up to $360 million. The event highlights a focus on oncology, cell therapy, and next-generation assets within the industry.PR NewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHCO, VRNT, SCPH on Behalf of ShareholdersHalper Sadeh LLC, an investor rights law firm, announced investigations into three companies—Soho House & Co Inc., Verint Systems Inc., and scPharmaceuticals Inc.—for potential violations of federal securities laws and/or breaches of fiduciary duties related to proposed sale transactions. The first two transactions involve acquisitions by private equity firms MCR and Thoma Bravo at premiums of $9.00 and $20.50 per share respectively, while scPharmaceuticals is being acquired by MannKind Corporation at $5.35 per share plus contingent value rights. The law firm is seeking additional consideration or relief for shareholders and is offering free consultations on a contingency fee basis.PR NewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NWE, BKH, MURA, SCPH on Behalf of ShareholdersHalper Sadeh LLC, an investor rights law firm, announced investigations into four separate proposed corporate transactions for potential violations of federal securities laws or breaches of fiduciary duties to shareholders. The transactions include NorthWestern Energy Group's proposed sale to Black Hills Corp (0.98 share exchange, resulting in 44%/56% ownership split), Mural Oncology's sale to XOMA Royalty Corporation ($2.035 per share plus up to $0.205 contingent), and scPharmaceuticals' sale to MannKind Corporation ($5.35 cash plus up to $1.00 CVR per share). The law firm is seeking affected shareholders to discuss legal rights and options on a contingency fee basis.GlobeNewswireSCPH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of scPharmaceuticals to MannKindWohl & Fruchter LLP is investigating the fairness of SCPH's sale to MannKind for $5.35 per share in cash plus a CVR, which is below multiple analysts' price targets. The firm is examining whether the board acted in shareholders' best interests and if all material information was disclosed.citybizMannKind To Acquire scPharmaceuticalsMannKind agreed to acquire scPharmaceuticals in a cash deal of up to $360 million, including milestone payments. The combined company will have an annualized run rate of over $370 million, with FUROSCIX sales up 96% year-over-year. The deal is expected to close in Q4 2025.PR NewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCPH, VTLE, CRGY on Behalf of ShareholdersHalper Sadeh LLC, an investor rights law firm, announced shareholder investigations into three proposed transactions: scPharmaceuticals Inc.'s sale to MannKind Corporation at $5.35 per share plus a contingent value right, Vital Energy Inc.'s sale to Crescent Energy Company via a stock-for-stock exchange, and Crescent Energy Company's merger with Vital Energy. The law firm stated it may seek increased consideration, additional disclosures, or other relief on behalf of shareholders, handling cases on a contingent fee basis.GlobeNewswirescPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111scPharmaceuticals received five USPTO notices of allowance for patents covering its furosemide formulation SCP-111. The company plans to file a supplemental NDA for the formulation this quarter, and the patents will join four existing ones. The allowances strengthen its intellectual property portfolio.